This year, the EAN Regional Teaching Course also has to adapt to changes. We are happy to announce the first Virtual Regional Teaching Course (RTC in Moscow, Russia 2021 - Virtual - ean.org ) on April 15-17, 2021.
Biomedical Alliance in Europe Calls for Strong Health Funding in Next EC Multiannual Financial Framework
November 6, 2025
BioMed Alliance and 17 other civil society organisations call on policy makers to ensure that the next multiannual EU budget will be fit-for-purpose to address current and future health threats.
Latest Posts
-
-
Clinical Fellowship Reports 2019
-
Breaking newsCOVID-19Research
Assessing brain capillaries in coronavirus disease 2019
February 25, 2021Assessing brain capillaries in coronavirus disease 2019 -
Breaking newsCOVID-19Research
Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021
February 25, 2021Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021 -
Breaking newsCOVID-19Research
Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection. The COVID A to Z randomized clinical trial
February 25, 2021Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection. The COVID A to Z randomized clinical trial -
Breaking newsCOVID-19Research
Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial
February 25, 2021Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial -
Breaking newsCOVID-19Research
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
February 25, 2021Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial -
Breaking newsCOVID-19Research
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
February 25, 2021Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia -
Breaking newsCOVID-19Research
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
February 25, 2021Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial -
Breaking newsCOVID-19Research
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
February 25, 2021Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study -
Breaking newsCOVID-19Research
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
February 25, 2021Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial -
Breaking newsCOVID-19Research
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
February 25, 2021Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial -
Breaking newsCOVID-19Research
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
February 25, 2021Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report -
Patients using angiotensin-II-stimulating antihypertensives have 45% lower risk to develop demenia compared to those that use angiotensin-II-inhibiting antihypertensives.
-
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders









